Summary & Overview
HCPCS Q4413: Cygnus Solo, Per Square Centimeter (Add-On)
HCPCS Level II code Q4413 designates the Cygnus solo product billed per square centimeter as an add-on supply in addition to a primary procedure. Nationally, add-on supply codes like this support granular billing for supplemental materials measured by area, ensuring procedural claims capture distinct supply costs and allowing payers and providers to account for material use separately from the primary service. Key payers commonly involved in national coverage and payment for such supplies include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what the code represents, typical clinical contexts and sites of service where it is billed, and the scope of payer coverage considered in national benchmarking. The publication reviews billing and coding context for area-based add-on supplies, expected documentation elements to support separate billing, and comparisons of payer handling and reimbursement policy where available. Data not available in the input will be noted as such in relevant sections.
Billing Code Overview
HCPCS Level II code Q4413 describes Cygnus solo, billed per square centimeter as an add-on supply to be listed separately in addition to a primary procedure. This code represents a supplemental product component measured and billed by surface area, used when the Cygnus solo material is applied as part of a primary clinical service.
-
Service type: Add-on supply or device component provided in conjunction with a primary procedure
-
Typical site of service: Facilities and outpatient settings where the primary procedure is performed, such as hospital outpatient departments, ambulatory surgical centers, and clinic procedure rooms
Clinical & Coding Specifications
Clinical Context
A patient with a chronic non-healing wound presents to a wound care clinic. The wound care specialist evaluates a full-thickness skin defect on the lower leg that has failed conservative therapy including dressings, debridement, and topical agents. The clinician determines that placement of a skin substitute product, specifically the Cygnus Solo biologic matrix, is appropriate to promote granulation and closure. In the clinic workflow the patient is prepared with wound cleansing and sharp or enzymatic debridement as needed, hemostasis is achieved, and the wound bed is measured in square centimeters. The clinician applies the Q4413 product sized to the wound and secures it per manufacturer instructions, often with a secondary dressing or negative-pressure wound therapy depending on wound characteristics. The procedure is documented with wound measurements, product units applied per square centimeter, indication, concurrent procedures (for example, debridement), and any applied modifiers to reflect multiple wounds or separate/anesthetic services. Typical follow-up visits occur within 1–2 weeks to assess integration of the matrix and wound progress.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a separate E/M visit is medically necessary and documented the same day as application |